Chadwick Jeremy G 4

What Happened

• Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics, exercised multiple option tranches and sold 300 shares on April 22, 2026. He exercised 100 shares at $30.17 (cost $3,017) and 200 shares at $43.50 (cost $8,700), for a total strike cost of $11,717. He sold 300 shares in an open-market transaction at $90.00 per share, generating $27,000 in proceeds. The filing also lists two derivative conversions reported as "Disposed" at $0.00 for 100 and 200 shares (see Key Details).

Key Details

• Transaction date: April 22, 2026.
• Exercises: 100 shares @ $30.17 ($3,017) and 200 shares @ $43.50 ($8,700) — total strike cost $11,717.
• Sale: 300 shares sold open market @ $90.00 = $27,000 proceeds.
• Reported derivative disposals: 100 shares @ $0.00 and 200 shares @ $0.00 (listed as dispositions of derivative conversions).
• Shares owned after transaction: not stated in the provided filing details.
• Footnotes: F1 — transactions were effected pursuant to a Rule 10b5-1 trading plan dated Dec 10, 2025. F2/F3 — referenced option grants vest monthly over 36 months from March 3, 2025 and March 1, 2024, respectively.
• Filing timing: Form filed Apr 24, 2026 reporting Apr 22 transactions (no late-filing flag provided in the summary).

Context

• The sequence — exercising options and selling an equal number of shares the same day — is consistent with an immediate sale following exercise (often done to cover exercise costs or follow a pre-arranged plan). Here the sale was executed under a 10b5-1 plan (per footnote), which is a pre-arranged trading plan that can indicate the sale was scheduled in advance rather than an ad hoc decision. As with most insider sales, this transaction is a disposition of shares and does not by itself indicate the insider’s view on the company’s prospects.